Indication
For the licence extension of low strength flutiform (50/5 µg) in children aged 5 to <12 years. This fixed-dose combination of fluticasone propionate and formoterol fumarate (flutiform inhaler) is indicated in the regular treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting β2 agonist) is appropriate: o For patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short-acting β2 agonist. Or o For patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist. flutiform 50 microgram/5 microgram inhaler is indicated in adults, adolescents and children aged 5 years and above.

Medicine details

Medicine name:
fluticasone/formoterol (Flutiform)
SMC ID:
SMC2178
Pharmaceutical company
Napp Pharmaceuticals Ltd
BNF chapter
Submission type
Abbreviated
Status
Publication due date:
10 June 2019
SMC meeting date:
07 May 2019